Arbutus Biopharma Corp (ABUS)
3.955
+0.10
(+2.46%)
USD |
NASDAQ |
Nov 05, 16:00
3.955
0.00 (0.00%)
After-Hours: 18:09
Arbutus Biopharma Revenue (Quarterly): 1.726M for June 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 1.726M |
| March 31, 2024 | 1.532M |
| December 31, 2023 | 2.145M |
| September 30, 2023 | 4.658M |
| June 30, 2023 | 4.651M |
| March 31, 2023 | 6.687M |
| December 31, 2022 | 6.245M |
| September 30, 2022 | 5.952M |
| June 30, 2022 | 14.24M |
| March 31, 2022 | 12.58M |
| December 31, 2021 | 3.206M |
| September 30, 2021 | 3.34M |
| June 30, 2021 | 2.329M |
| March 31, 2021 | 2.113M |
| December 31, 2020 | 2.386M |
| September 30, 2020 | 1.523M |
| June 30, 2020 | 1.514M |
| March 31, 2020 | 1.491M |
| December 31, 2019 | 1.618M |
| September 30, 2019 | 3.061M |
| June 30, 2019 | 0.653M |
| March 31, 2019 | 0.679M |
| December 31, 2018 | 1.678M |
| September 30, 2018 | 1.587M |
| June 30, 2018 | 1.244M |
| Date | Value |
|---|---|
| March 31, 2018 | 1.436M |
| December 31, 2017 | 2.534M |
| September 30, 2017 | 6.892M |
| June 30, 2017 | 1.039M |
| March 31, 2017 | 0.235M |
| December 31, 2016 | -0.195M |
| September 30, 2016 | 0.774M |
| June 30, 2016 | 0.309M |
| March 31, 2016 | 0.603M |
| December 31, 2015 | 11.09M |
| September 30, 2015 | 4.065M |
| June 30, 2015 | 3.44M |
| March 31, 2015 | 4.682M |
| December 31, 2014 | 4.35M |
| September 30, 2014 | 4.362M |
| June 30, 2014 | 1.811M |
| March 31, 2014 | 4.43M |
| December 31, 2013 | 7.527M |
| September 30, 2013 | 2.963M |
| June 30, 2013 | 2.844M |
| March 31, 2013 | 2.132M |
| December 31, 2012 | 3.709M |
| September 30, 2012 | 3.097M |
| June 30, 2012 | 3.559M |
| March 31, 2012 | 3.572M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
1.491M
Minimum
Mar 2020
14.24M
Maximum
Jun 2022
4.207M
Average
2.386M
Median
Dec 2020
Revenue (Quarterly) Benchmarks
| Biomarin Pharmaceutical Inc | 745.74M |
| GlycoMimetics Inc | -- |
| FibroGen Inc | 50.64M |
| Cidara Therapeutics Inc | 0.302M |
| Cue Biopharma Inc | 2.658M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -19.80M |
| Total Expenses (Quarterly) | 23.10M |
| EPS Diluted (Quarterly) | -0.11 |
| Enterprise Value | 586.71M |
| Profit Margin (Quarterly) | -1.15K% |
| Earnings Yield | -11.38% |
| Normalized Earnings Yield | -11.26 |